tiprankstipranks

Amylyx upgraded to Outperform from Neutral at Mizuho

Mizuho upgraded Amylyx (AMLX) to Outperform from Neutral with a price target of $7, up from $3, after introducing first-time projections for avexitide in post-bariatric hypoglycemia as well as adding back model contributions from AMX0035 in progressive supranuclear palsy and Wolfram Syndrome.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue